Moreover, a study found that the synergistic effects of KAI1/CD82 and ganglioside GM3 or GM2/GM3 were able to inhibit HCC cell motility and migration via epidermal growth factor receptor (EGFR) or cMet-activated Pl3K/Akt signaling pathway [20]. This evidence concerns the gene EGFR and hepatocellular carcinoma.